Published :
Tables : 64
Figures : 45
Category : Healthcare
No. of Pages : 220
Report Code : HC-U3272
Continuous Bioprocessing Market is predicted to value over USD 7 billion by 2027 end with a CAGR of over 8.5% during the forecast period 2020 to 2027. The rising insistence for biopharmaceutical products, development of advanced technologies pertaining to continuous bioprocessing, bolstered support from government for manufacturing biopharmaceuticals are some of the driving factors contributing to the growth of the market. The consistent production of biopharmaceuticals on a commercial and clinical level with the use of flexible facilities is called continuous bioprocessing. The continuous bioprocessing market growth is primarily driven by increased development of novel technologies, rising insistence for biopharmaceuticals, increased support from the government for manufacturing biopharmaceuticals. There has been a significant escalation in the occurrence of chronic disorders across the world. As per the American Pharmaceutical Review, the insistence for antibody products has escalated and with the biologic license application, the antibody products account for over 65% of all the biopharmaceutical products. Furthermore, as per the journal, over 80% of the products are in phase 3 of the development stage while over 90% of products are currently in phase 1 and phase 2 of development. Moreover, with complexities occurring in clinical trials, the financial assistance provided by the government for research and development activities has increased significantly. For instance, the government of India announced the ‘Pharma Vision 2020’ in 2018 and this aims at reducing the time required for approving new sites, thereby escalating the capacity of producing biopharmaceuticals. Additionally, the government has decided to completely favour FDI for the pharmaceutical industry resulting in the rise of collaborations between the government and the pharmaceutical giants. Furthermore, The National Institute of Health of the United States partnered with over 10 biopharma companies in 2017 to announce the ‘Partnership for Accelerating Cancer Therapies’, which is a private-public research collaboration set for five years. This collaboration shall help in developing immunotherapies for cancer with a total investment of over USD 200 million. Moreover, Japan’s Ministry of Health, Labour and Welfare in 2015 announced the ‘Sakigake’ scheme that aimed at accelerating the launch time for novel drugs. However, high contamination risks pertaining to continuous processing, operational complexities related to continuous processing and a lack of professionals that work into bioprocessing are some of the factors restraining the market growth. Market Segmentation: By Product Filtration Systems and Consumables Chromatography Systems and Consumables Bioreactors Cell Culture Media and Reagents Others By End User Pharmaceutical and Biotechnology Companies Contract Development and Manufacturing Organizations Academics and Research Institutes By Region North America Europe Asia-Pacific Latin America Middle East and Africa The global market is fragmented into product, end user and region. The product segment is categorised into filtration systems and consumables, chromatography systems and consumables, bioreactors and cell culture media and reagents. The filtration system and consumables segment held the largest continuous bioprocessing market share owing to rising acceptance of single use filters for the purification of biopharmaceutical products and frequent usage of related products are bolstering the lead of the segment. The end user segment is divided into pharmaceutical and biotechnology companies, contract development and manufacturing organizations and academics and research institutes. The pharmaceutical and biotechnology companies are anticipated to lead the market due to the rising acceptance of products and consumables required for manufacturing biopharmaceuticals by these companies. Regional Analysis: The North America region is expected to dominate the market during the forecast period owing to a strong presence of prominent market players in the region and the rising support by the government by assigning funds for research and development of continuous bioprocessing. However, the Asia Pacific region is predicted to grow with a substantial rate over the forecasted timeframe owing to a rise in the occurrence of chronic disorders, increased emphasis of the government in improving the biopharmaceutical industry. Additionally, important business expansions by key market players in the region shall augment the market growth. Competitive Landscape: Some of the prominent players of the market are GE Healthcare, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Bio-Rad Laboratories, Inc., Sartorius AG, Repligen Corporation, Eppendorf AG, 3M Company, Applikon Biotechnology B.V. FutureWise Key Takeaways: Growth prospects SWOT analysis Key market trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global continuous bioprocessing market by product, by end user and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
The rising insistence for biopharmaceutical products, development of advanced technologies pertaining to continuous bioprocessing, bolstered support from government for manufacturing biopharmaceuticals are some of the driving factors contributing to the growth of the market. The consistent production of biopharmaceuticals on a commercial and clinical level with the use of flexible facilities is called continuous bioprocessing.
The continuous bioprocessing market growth is primarily driven by increased development of novel technologies, rising insistence for biopharmaceuticals, increased support from the government for manufacturing biopharmaceuticals. There has been a significant escalation in the occurrence of chronic disorders across the world. As per the American Pharmaceutical Review, the insistence for antibody products has escalated and with the biologic license application, the antibody products account for over 65% of all the biopharmaceutical products. Furthermore, as per the journal, over 80% of the products are in phase 3 of the development stage while over 90% of products are currently in phase 1 and phase 2 of development.
Moreover, with complexities occurring in clinical trials, the financial assistance provided by the government for research and development activities has increased significantly. For instance, the government of India announced the ‘Pharma Vision 2020’ in 2018 and this aims at reducing the time required for approving new sites, thereby escalating the capacity of producing biopharmaceuticals. Additionally, the government has decided to completely favour FDI for the pharmaceutical industry resulting in the rise of collaborations between the government and the pharmaceutical giants. Furthermore, The National Institute of Health of the United States partnered with over 10 biopharma companies in 2017 to announce the ‘Partnership for Accelerating Cancer Therapies’, which is a private-public research collaboration set for five years. This collaboration shall help in developing immunotherapies for cancer with a total investment of over USD 200 million. Moreover, Japan’s Ministry of Health, Labour and Welfare in 2015 announced the ‘Sakigake’ scheme that aimed at accelerating the launch time for novel drugs.
However, high contamination risks pertaining to continuous processing, operational complexities related to continuous processing and a lack of professionals that work into bioprocessing are some of the factors restraining the market growth.
Market Segmentation:
By Product
By End User
By Region
The global market is fragmented into product, end user and region. The product segment is categorised into filtration systems and consumables, chromatography systems and consumables, bioreactors and cell culture media and reagents. The filtration system and consumables segment held the largest continuous bioprocessing market share owing to rising acceptance of single use filters for the purification of biopharmaceutical products and frequent usage of related products are bolstering the lead of the segment. The end user segment is divided into pharmaceutical and biotechnology companies, contract development and manufacturing organizations and academics and research institutes. The pharmaceutical and biotechnology companies are anticipated to lead the market due to the rising acceptance of products and consumables required for manufacturing biopharmaceuticals by these companies.
Regional Analysis:
The North America region is expected to dominate the market during the forecast period owing to a strong presence of prominent market players in the region and the rising support by the government by assigning funds for research and development of continuous bioprocessing. However, the Asia Pacific region is predicted to grow with a substantial rate over the forecasted timeframe owing to a rise in the occurrence of chronic disorders, increased emphasis of the government in improving the biopharmaceutical industry. Additionally, important business expansions by key market players in the region shall augment the market growth.
Competitive Landscape:
Some of the prominent players of the market are GE Healthcare, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Bio-Rad Laboratories, Inc., Sartorius AG, Repligen Corporation, Eppendorf AG, 3M Company, Applikon Biotechnology B.V.
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances 5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.2 Market Restraint Analysis 5.1.3 Industry Challenges 6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape 7. Continuous Bioprocessing Market, By Product Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 7.1 Filtration Systems and Consumables 7.2 Chromatography Systems and Consumables 7.3 Bioreactors 7.4 Cell Culture Media and Reagents 7.5 Others 8. Continuous Bioprocessing Market, By End User Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 8.1 Pharmaceutical and Biotechnology Companies 8.2 Contract Development and Manufacturing Organizations 8.3 Academics and Research Institutes 9. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Mn) Analysis By Country, 2015-2019 9.2.1. U.S. 9.2.2. Canada 9.2.3. Mexico 9.2.4. Rest of North America 9.3 Market Size (USD Mn) Forecast for North America 2020-2027 10. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 10.1. Introduction 10.2. Regional Market Trends 10.3. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 10.3.1. Brazil 10.3.2. Venezuela 10.3.3. Argentina 10.3.4. Rest of Latin America 10.4 Market Size (US$ Mn) Forecast for Latin America 2020-2027 11. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 11.2.1. Germany 11.2.2. U.K 11.2.3. France 11.2.4. Italy 11.2.5 Switzerland 11.2.6. Spain 11.2.7. Russia 11.2.8. Poland 11.2.9. Rest of Western Europe 11.3 Market Size (US$ Mn) Forecast for Europe 2020-2027 12. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1 Introduction 12.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 12.2.1 Japan 12.2.2 China 12.2.3 Singapore 12.2.4 Korea 12.2.5 India 12.2.6 Australia and New Zealand 12.2.7 ASEAN 12.2.8 Rest of Asia Pacific 12.3 Market Size (US$ Mn) Forecast for Asia Pacific 2020-2027 13. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1 UAE 13.2 South Africa 13.3 Egypt 13.4 Saudi Arabia 13.5 Rest of MEA 14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 14.1 GE Healthcare 14.1.1. Company Overview (HQ, Business Segments, Employee Strength) 14.1.2. Product Portfolio 14.1.3. SWOT Analysis 14.1.4. Financial Overview 14.1.5. Strategic Overview 14.2 Thermo Fisher Scientific Inc. 14.2.1. Company Overview (HQ, Business Segments, Employee Strength) 14.2.2. Product Portfolio 14.2.3. SWOT Analysis 14.2.4. Financial Overview 14.2.5. Strategic Overview 14.3 Merck KGaA 14.3.1. Company Overview (HQ, Business Segments, Employee Strength) 14.3.2. Product Portfolio 14.3.3. SWOT Analysis 14.3.4. Financial Overview 14.3.5. Strategic Overview 14.4 Danaher Corporation 14.4.1. Company Overview (HQ, Business Segments, Employee Strength) 14.4.2. Product Portfolio 14.4.3. SWOT Analysis 14.4.4. Financial Overview 14.4.5. Strategic Overview 14.5 Bio-Rad Laboratories, Inc. 14.5.1. Company Overview (HQ, Business Segments, Employee Strength) 14.5.2. Product Portfolio 14.5.3. SWOT Analysis 14.5.4. Financial Overview 14.5.5. Strategic Overview 14.6 Sartorius AG 14.6.1. Company Overview (HQ, Business Segments, Employee Strength) 14.6.2. Product Portfolio 14.6.3. SWOT Analysis 14.6.4. Financial Overview 14.6.5. Strategic Overview 14.7 Repligen Corporation 14.7.1. Company Overview (HQ, Business Segments, Employee Strength) 14.7.2. Product Portfolio 14.7.3. SWOT Analysis 14.7.4. Financial Overview 14.7.5. Strategic Overview 14.8 Eppendorf AG 14.8.1. Company Overview (HQ, Business Segments, Employee Strength) 14.8.2. Product Portfolio 14.8.3. SWOT Analysis 14.8.4. Financial Overview 14.8.5. Strategic Overview 14.9 3M Company 14.9.1. Company Overview (HQ, Business Segments, Employee Strength) 14.9.2. Product Portfolio 14.9.3. SWOT Analysis 14.9.4. Financial Overview 14.9.5. Strategic Overview 14.10 Applikon Biotechnology B.V. 14.10.1. Company Overview (HQ, Business Segments, Employee Strength) 14.10.2. Product Portfolio 14.10.3. SWOT Analysis 14.10.4. Financial Overview 14.10.5. Strategic Overview 15. Impact of COVID-19 15.1. Positive influence on the healthcare industry 15.2. The financial disruption of the manufacturing sector 15.3. Impact of COVID-19 on emerging companies 15.4. Significant mandates in the healthcare regulations initiated by administrations 15.5. The overall economic slowdown of the developing and developed nations 16. Competitive Intelligence and Competitive Matrix 16.1 Competitive Intelligence 16.2 Competitive Matrix 17. Major Deals and Strategic Alliances Analysis 17.1 Joint ventures 17.2 Mergers and acquisitions 17.3 Licensing and partnerships 17.4 Technology Collaborations 17.5 Strategic Divestments 17.6 Market Entry Strategies 18. Relevant Case Studies and Latest News Updates 19. Research Sources and List of Primary Contacts of this Study 20. Key Market Takeaway Points from the Market Analysts at Future Market Analytics
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics